Drugs / BN104
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06746519 | Dec 2024 → Dec 2025 overdue | acute myeloid leukemia | Chen Suning | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06052813 | Oct 2023 → Dec 2026 expected | acute myeloid leukemia with NPM1 somatic mutations, adult acute lymphoblastic leukemia | Servier | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07101497 | Aug 2025 → Dec 2027 expected | acute myeloid leukemia, MLL gene rearrangement, disease related to hematopoietic stem cell transplant | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06724549 Comparator | Jan → Feb 2025 | — | BioNova Pharmaceuticals (Shanghai) LTD. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BN104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06746519 ↗ |
| Action | Inhibit | “Menin Inhibitor BN104” NCT06052813 ↗ |
| Modality | Small molecule | — CHEMBL6068545 ↗ |
| Route | Oral | “administered orally once daily” NCT06052813 ↗ |